Halozyme Therapeutics (NASDAQ:HALO) Releases FY25 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $4.95-$5.35 for the period, compared to the consensus estimate of $4.83. The company issued revenue guidance of $1.150-$1.225 billion, compared to the consensus revenue estimate of $1.16 billion. Halozyme Therapeutics also updated its FY24 guidance to $4.00-$4.20 EPS.

Analysts Set New Price Targets

HALO has been the subject of several recent analyst reports. Wells Fargo & Company cut shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their price target for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. JMP Securities increased their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Piper Sandler lifted their price objective on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a research note on Monday, November 4th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $68.00 price objective on shares of Halozyme Therapeutics in a report on Monday, December 30th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $61.11.

Halozyme Therapeutics Stock Up 1.3 %

NASDAQ HALO opened at $51.19 on Wednesday. The company has a market capitalization of $6.51 billion, a P/E ratio of 16.95, a PEG ratio of 0.44 and a beta of 1.24. Halozyme Therapeutics has a 12 month low of $33.15 and a 12 month high of $65.53. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The company’s 50 day simple moving average is $50.10 and its 200 day simple moving average is $54.00.

Insider Buying and Selling at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. The trade was a 18.65 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 2.70% of the stock is owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.